期刊文献+
共找到3篇文章
< 1 >
每页显示 20 50 100
电动车时速应限制在35km之内 被引量:1
1
作者 何祚庥 《电动自行车》 2010年第2期3-3,共1页
电动车的新国标考虑到“发展”的要求。时速应以限制在35km之内为宜,车重应在人体重量基础上“打点折”。
关键词 电动车 时速标准 建议
下载PDF
A Multi-Hop Moving Zone(MMZ) Clustering Scheme Based on Cellular-V2X 被引量:3
2
作者 Zahid Khan Pingzhi Fan 《China Communications》 SCIE CSCD 2018年第7期55-66,共12页
A clustering scheme based on pure V2V communications has two prominent issues i.e. broadcast storm and network disconnection. The application of the fifth generation(5G) technology to vehicular networks is an optimal ... A clustering scheme based on pure V2V communications has two prominent issues i.e. broadcast storm and network disconnection. The application of the fifth generation(5G) technology to vehicular networks is an optimal choice due to its wide coverage and low latency features. In this paper, a Multihop Moving Zone(MMZ) clustering scheme is proposed by combining IEEE 802.11p with the 3rd Generation Partnership Project(3GPP) 5G cellular technology. In MMZ, vehicles are clustered up-to three hops using V2V communications based on IEEE 802.11 p aiming to reduce excessive cellular hand-off cost. While the zonal heads(ZHs) i.e. cluster heads(CHs) are selected by cellular-V2X(C-V2X) on the basis of multi-metrics i.e. relative speed, distance and link life time(LLT). The main goal of MMZ is to form stable clusters achieving high packet delivery and low latency. The simulation results using ns3 show that, 5G wide range technology significantly improves the stability of MMZ in term of ZH duration and change rate. The average Data Packet Delivery Ratio(DPDR) and E2E latency are also improved as compared to the existing clustering schemes. 展开更多
关键词 clustering 3GPP 5G cluster head stable clusters reliability and latency
下载PDF
A Review of an Unorthodox Argatroban Infusion Rate for Anticoagulation in a Patient Case
3
作者 Erin Barnett Loesch Christopher Ryan Boldi 《Journal of Pharmacy and Pharmacology》 2017年第4期189-193,共5页
Argatroban is an intravenous DTI (direct synthetic thrombin inhibitor) that is not routinely used for anticoagulation; thus, expertise surrounding its use is very limited. Therefore, this case reviews an unusually h... Argatroban is an intravenous DTI (direct synthetic thrombin inhibitor) that is not routinely used for anticoagulation; thus, expertise surrounding its use is very limited. Therefore, this case reviews an unusually high argatroban infusion rate, which was needed to prevent further emboli formation in a patient. In this case, a 61-year-old Caucasian male patient exhibited heparin resistance during an intraoperative vascular procedure as measured by activated clotting time and PTT (partial thromboplastin time). The patient had multiple occlusions in his right lower extremities and underwent embolectomies of the right popliteal and posterior tibial arteries. The clinical pharmacist was consulted to manage the argatroban infusion once heparin was discontinued. The therapeutic window required a PTr of 1.5-3 times the patient baseline (35-75 s). The patient was reported to be 89 kg with a baseline PTT of 24.7 s and INR (international normalized ratio) of 0.98. The starting dose ofargatroban was initiated by the pharmacist at 2 mcg/kg/min (10.7 mL/h) as the patient did not have hepatic failure or sepsis. The patient was maintained on argatroban in the therapeutic PTT window for more than 72 h; however, frequent and aggressive dose increases, to a final rate of 7.5 mcg/kg/min (40 mL/h), were needed to maintain the therapeutic PTT level. From the case, the cause of heparin resistance still has not been determined despite a hematologic work-up; however, this patient required an unusually high infusion rate of argatroban to maintain a therapeutic PTT during the hospital course before being changed to an anticoagulation regimen for discharge. 展开更多
关键词 ANTICOAGULATION ARGATROBAN direct thrombin inhibitor heparin resistance partial thromboplastin time.
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部